Wodzicki A M, Coopland A T
Can Med Assoc J. 1974 Apr 20;110(8):905-9.
The effect on the coagulation mechanism of lactation suppressants was determined by comparing observations on a group of untreated women and two other groups, one receiving Vallestril (methallenestrill 20 mg) and the other Ortho-Novum 5 (5 mg norethindrone and 0.075 mg mestranol). Blood was drawn on the first, fourth and tenth days post partum. Patients given Ortho-Novum 5 showed a continued significant elevation of levels of factors VIII and IX for the duration of the study, and the partial thromboplastin time reflected this increase on days 4 and 10. Vallestril appeared to have the same effect on factors VIII and IX, although to a lesser, nonsignificant degree. In addition, the day 10 levels of fibrinogen and factors VII and X, as well as platelet adhesiveness, of the untreated group were lower than those of the groups undergoing treatment, although the medication had been discontinued five days previously. However, this difference was not statistically significant.In view of the growing evidence of the increased incidence of thromboembolic disease during the puerperium, it is perhaps unwise to give drugs that cause changes in the plasma coagulation system, such as those we have described, to patients who are already in a hypercoagulable state.
通过比较一组未治疗的妇女以及另外两组妇女（一组服用瓦莱斯特里尔（炔雌醇甲醚20毫克），另一组服用炔诺酮5号（5毫克炔诺酮和0.075毫克炔雌醇甲醚））的观察结果，确定了哺乳期抑制药物对凝血机制的影响。在产后第1天、第4天和第10天采集血液。服用炔诺酮5号的患者在研究期间因子VIII和IX水平持续显著升高，部分凝血活酶时间在第4天和第10天反映出这种升高。瓦莱斯特里尔对因子VIII和IX似乎有相同的作用，尽管程度较小且不显著。此外，未治疗组第10天的纤维蛋白原、因子VII和X水平以及血小板黏附性均低于接受治疗的组，尽管药物在五天前已停用。然而，这种差异无统计学意义。鉴于越来越多的证据表明产褥期血栓栓塞性疾病的发病率增加，对于已经处于高凝状态的患者，给予会引起血浆凝血系统变化的药物（如我们所描述的那些药物）可能是不明智的。
